The Food and Drug Administration approves a new treatment for advanced breast cancer
In a pioneering medical step reflecting the ongoing advancements in the healthcare sector, the Saudi Food and Drug Authority (SFDA) announced the registration and approval of a new treatment for advanced breast cancer . The new medication, named Camizestrant, is intended for adult patients with locally advanced or metastatic breast cancer. It specifically targets HER2-positive and HER2-negative breast cancer, particularly when a genetic mutation in the estrogen receptor 1 (ESR1) gene is present during first-line hormonal therapy, in conjunction with standard treatment.
A historic development in providing a new treatment for breast cancer
Historically, breast cancer has been one of the most common cancers among women, both locally and globally. For many years, advanced or metastatic cases posed a significant challenge to healthcare systems, as treatment options were often limited to traditional chemotherapy or older hormonal therapies to which the body could develop resistance over time. With scientific advancements, the need for targeted and precise treatments has become increasingly apparent. The approval of this drug is a response to this need. Camisestrant is a selective inhibitor of estrogen receptors found in breast cancer cells. The drug works through an innovative mechanism of action that inhibits these receptors within cells, whether in their normal or mutated form, which directly contribute to the growth and proliferation of cancer cells, thus effectively limiting tumor growth and its spread to other organs.
The impact of accreditation locally and globally
This accreditation represents an exceptional achievement and a precedent set by the Saudi Food and Drug Authority (SFDA) among leading global regulatory bodies. Domestically, this decision ensures faster access to innovative treatment options for patients in the Kingdom through the Promising Drugs Program, thus alleviating the suffering of patients and their families. Regionally and internationally, this step reinforces the Kingdom's position as a leader in adopting cutting-edge medical technologies and underscores the capability of its healthcare system to evaluate and approve complex medications with a speed and efficiency surpassing many similar international bodies.
Proven effectiveness and significant improvement in quality of life
The authority confirmed that the decision to approve the product's registration followed a comprehensive and rigorous scientific evaluation of its efficacy, safety, and quality. Based on all the presented clinical evidence and data, key indicators showed a statistically significant reduction in the risk of disease progression of up to 56% compared to continued standard hormone therapy. The data also showed that the median progression-free survival was approximately 16 months for patients using the new product, compared to approximately 9 months for patients using standard therapy.
In addition, secondary indicators related to survival to second disease exacerbation supported the significant therapeutic benefit of the drug, showing an additional 37% reduction in risk. Patient-reported outcome measures also demonstrated significant improvements in quality of life and delays in the deterioration of overall health and disease-related symptoms. Regarding safety, clinical studies revealed that the most common side effects included transient visual effects, such as flashing lights or a briefly lingering image after the visual stimulus has disappeared, as well as other mild visual effects and, in some cases, bradycardia—all of which are medically manageable.
In line with the objectives of Saudi Vision 2030
In conclusion, this medical accreditation reflects the Saudi Food and Drug Authority's ongoing efforts to support pharmaceutical innovation and empower patients with rapid and safe access to modern treatment options. These significant steps enhance the quality of healthcare and improve the efficiency of treatment services provided in hospitals and specialized centers, aligning perfectly with the objectives of the Health Sector Transformation Program, a key component of the Kingdom's Vision 2030 aimed at building a vibrant society and a comprehensive and effective healthcare system.
